INSERM UMR_S 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France.
Faculté de Médecine, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre, France.
Cells. 2021 Feb 23;10(2):477. doi: 10.3390/cells10020477.
Pulmonary arterial hypertension (PAH) is a severe cardiovascular disease that is caused by the progressive occlusion of the distal pulmonary arteries, eventually leading to right heart failure and death. Almost 40% of patients with PAH are iron deficient. Although widely studied, the mechanisms linking between PAH and iron deficiency remain unclear. Here we review the mechanisms regulating iron homeostasis and the preclinical and clinical data available on iron deficiency in PAH. Then we discuss the potential implications of iron deficiency on the development and management of PAH.
肺动脉高压（PAH）是一种严重的心血管疾病，由远端肺动脉的进行性闭塞引起，最终导致右心衰竭和死亡。几乎 40%的 PAH 患者存在铁缺乏。尽管已经广泛研究，但 PAH 与铁缺乏之间的关联机制仍不清楚。在这里，我们回顾了调节铁稳态的机制以及 PAH 中铁缺乏的临床前和临床数据。然后我们讨论了铁缺乏对 PAH 发展和管理的潜在影响。
